Contents

Search

Million Women Study

Study characteristics: - 700,000 women mean age 58 grouped according to hormone replacement therapy (HRT) - estrogen alone - estrogen combined with continuous progesterone - estrogen combined with cyclic progesterone - none Results: (3.4 years duration) - relative risk of endometrial cancer with HRT vs none - estrogen alone (1.45) - estrogen combined with continuous progesterone (0.71) - estrogen combined with cyclic progesterone (1.05) - relative risk of endometrial conacer for obese vs non obese women = 4.0 (no HRT) - among obese women, continuous & cyclic HRT reduced risk or endometrial cancer Conclusions: - Since breast cancer is much more common than endometrial cancer, the increase risk of breast cancer with HRT outweighs any reduction in endometrial cancer

Related

breast cancer endometrial cancer (carcinoma) hormone replacement therapy (HRT); estrogen replacement therapy; postmenopausal hormone replacement therapy

General

clinical trial

References

  1. Journal Watch 25(13):108, 2005 Beral V, Bull D, Reeves G; Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005 Apr 30-May 6;365(9470):1543-51. PMID: 15866308